Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
08 Oct 2021
08 Oct 2021
Historique:
received:
16
08
2021
revised:
16
11
2021
accepted:
23
09
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Breast cancer is the leading cause of cancer-related deaths among women worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is significantly associated with higher breast tumor proliferation rates. MFCH401, a 9-mer specific peptide fragment (DTILWKDIF) in the extracellular domain of the HER2 protein, is an attractive epitope for developing anti-HER2 cancer vaccines. However, the inherent low immunogenicity of MFCH401 limits its application. Herein, to induce a stronger and more durable immune response, a self-adjuvanting MFCH401-conjugated multiple-component anti-HER2 cancer vaccine was designed and synthesized by incorporating MFCH401 with lipopeptide Pam
Identifiants
pubmed: 35497522
doi: 10.1039/d1ra06146a
pii: d1ra06146a
pmc: PMC9042281
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33814-33822Commentaires et corrections
Type : ErratumIn
Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Angew Chem Int Ed Engl. 2018 Jul 2;57(27):8219-8224
pubmed: 29768704
J Med Chem. 2020 Oct 22;63(20):11691-11706
pubmed: 32960056
Chem Commun (Camb). 2016 Jun 18;52(48):7572-5
pubmed: 27216415
Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1699-703
pubmed: 24449389
Immunotherapy. 2015;7(11):1159-68
pubmed: 26567563
Methods Mol Biol. 2016;1403:779-96
pubmed: 27076167
Chem Asian J. 2019 Dec 2;14(23):4268-4273
pubmed: 31591824
Methods Mol Biol. 2016;1403:797-817
pubmed: 27076168
J Hematol Oncol. 2019 Oct 29;12(1):111
pubmed: 31665051
Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1635-9
pubmed: 21308921
Front Chem. 2015 Oct 23;3:60
pubmed: 26557640
Medchemcomm. 2019 Jul 12;10(12):2073-2077
pubmed: 32133105
J Immunother Cancer. 2018 Dec 12;6(1):146
pubmed: 30541631
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Arch Immunol Ther Exp (Warsz). 2020 Jan 9;68(1):2
pubmed: 31915932
Front Immunol. 2013 Oct 09;4:318
pubmed: 24130558
Science. 2018 Mar 23;359(6382):1355-1360
pubmed: 29567706
Front Immunol. 2020 Nov 12;11:599083
pubmed: 33281825
Angew Chem Int Ed Engl. 2013 Jun 3;52(23):6106-10
pubmed: 23616304
Angew Chem Int Ed Engl. 2020 Sep 28;59(40):17705-17711
pubmed: 32583549
J Transl Med. 2012 Jan 05;10:4
pubmed: 22221900
Chemistry. 2013 Feb 4;19(6):1962-70
pubmed: 23280874
Hum Pathol. 2020 Jan;95:137-148
pubmed: 31682887
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
Nat Chem Biol. 2007 Oct;3(10):663-7
pubmed: 17767155
Immunol Invest. 2015;44(8):817-36
pubmed: 26575466
Cancer Treat Rev. 2020 Aug;88:102033
pubmed: 32534233
Front Immunol. 2019 May 29;10:1144
pubmed: 31191528